NV-354

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H15NO4S
Molecular Weight	233.285
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of NV-354

Structure Search

SMILES

COC(=O)CCC(=O)SCCNC(C)=O

InChI

InChIKey=LCEITCPWQIJXGQ-UHFFFAOYSA-N

InChI=1S/C9H15NO4S/c1-7(11)10-5-6-15-9(13)4-3-8(12)14-2/h3-6H2,1-2H3,(H,10,11)

HIDE SMILES / InChI

Molecular Formula	C9H15NO4S
Molecular Weight	233.285
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Wed Apr 02 17:42:49 GMT 2025` Edited by `admin` on `Wed Apr 02 17:42:49 GMT 2025`
Record UNII	4GF65YYK2S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NV354

Preferred Name

English

NV-354

Common Name

English

Butanoic acid, 4-[[2-(acetylamino)ethyl]thio]-4-oxo-, methyl ester

Common Name

English

Methyl 4-{[2-(acetamino)ethyl]sulfanyl}-4-oxobutanoate

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

933323

Created by admin on Wed Apr 02 17:42:49 GMT 2025 , Edited by admin on Wed Apr 02 17:42:49 GMT 2025

Code System Code Type Description

SMS_ID

300000051296

Created by admin on Wed Apr 02 17:42:49 GMT 2025 , Edited by admin on Wed Apr 02 17:42:49 GMT 2025

PRIMARY

CAS

866465-21-6

Created by admin on Wed Apr 02 17:42:49 GMT 2025 , Edited by admin on Wed Apr 02 17:42:49 GMT 2025

PRIMARY

FDA UNII

4GF65YYK2S

Created by admin on Wed Apr 02 17:42:49 GMT 2025 , Edited by admin on Wed Apr 02 17:42:49 GMT 2025

PRIMARY

PUBCHEM

86075622

Created by admin on Wed Apr 02 17:42:49 GMT 2025 , Edited by admin on Wed Apr 02 17:42:49 GMT 2025

PRIMARY

Related Record Type Details


					AB6MNQ6J6L

METABOLITE ACTIVE -> PRODRUG

Comments:

Developed for chronic oral treatment of Leigh syndrome, a severe primary mitochondrial disease that usually debuts at one to two years of age.

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
BRAIN/PLASMA RATIO	PHARMACOKINETIC